Will the FDA approve the skin cancer vaccine by...?
Market Rules
This event predicts whether the FDA grants approval of intismeran autogene (mRNA-4157/V940), the individualized neoantigen therapy developed by Moderna and Merck, for any indication by each of the dates below, 11:59 PM ET. Each market covers one deadline and resolves independently; a qualifying approval resolves every market whose deadline has not yet passed to "Yes". Resolution is based on official information from the FDA, and a consensus of credible reporting may also be used.